Search

Search

このページは機械翻訳されています。他のページは英語で表示される場合があります。 View in English

ホーム
...
研究分野生物医学と臨床科学腫瘍学とがん発生分子標的
CLK1/SRSF7を標的とする軸依存の代替スプライシングは,臓管内腺がんを化学療法と免疫療法に敏感にする.

CLK1/SRSF7を標的とする軸依存の代替スプライシングは,臓管内腺がんを化学療法と免疫療法に敏感にする.

Chun Zhang ¹, Yinhao Chen ², Shuncang Zhu ², Zuwei Wang ², Hongyi Lin ², Jinpeng Lu ², Haoxiang Zhang ², Yueyi Weng ³, Xiaoxiao Huang ², Ge Li ⁴, Yongding Wu ², Zhiyuan Li ², Jianfei Hu ⁵, Chengke Xie ², Jianlin Lai ², Yifeng Tian ², Chengyu Liao ², Shi Chen ²

Chun Zhang ¹, Yinhao Chen ², Shuncang Zhu ²

¹Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China; Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou 350001, China; Department of General Surgery, Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, China.
²Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China; Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou 350001, China.
³Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China.
⁴Department of Hepatobiliary Surgery, Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.
⁵Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou 350001, China.

⁰Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China; Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou 350001, China; Department of General Surgery, Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, China.

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy +

|

2025年8月21日

関連する実験動画

These videos have been matched automatically. Contact us if they are not relevant.

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in <em data-lazy-src=

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

See all related videos

PubMedで要約を見る

まとめ

この要約は機械生成です。

循環型RNA cALG8は,DNA修復と免疫抑制を強めることで,臓がんにおけるゲムシタビン耐性を促進する. この経路をアンチセンスオリゴヌクレオチドで標的にすると,臓管内腺がんに対する治療の可能性が示されます.

科学分野

分子腫瘍学
ガン治療薬
RNA 生物学

背景

臓管内腺癌 (PDAC) は,ゲムシタビン耐性による高い死亡率を示しています.
化学抵抗の分子メカニズムの理解は効果的な治療法の開発に不可欠です

研究の目的

PDACにおけるゲムシタビン耐性の分子メカニズムを解明する.
薬剤耐性を引き起こす新しい腫瘍原性因子を特定する.
ゲムシタビン耐性に対する標的治療戦略を開発する.

主な方法

円形のRNA (circRNA) 配列と液体染色体質谱 (LC-MS) は,cALG8および関連するRNA結合タンパク質 (RBPs) を特定した.
cALG8の機能を調査するために,分子生物学技術,単細胞シーケンシング,患者由来オーガノイド (PDO),患者由来キセノ移植 (PDX) モデルを使用した.
cALG8を標的としたアンチセンセスオリゴヌクレオチド (ASO) が開発され,in vivoで評価された.

主要な成果

循環型RNA cALG8は,ゲムシタビン耐性PDACで高度に発現し,代替スプライシングによって化学抵抗と免疫抑制を促進する.
cALG8は,CLK1媒介によるSRSF7のリン酸化を促進し,ATM発現の強化につながります (ATM203変種).
このメカニズムは,ゲムシタビン効果に対抗して,DNA損傷の修復と免疫微環境の改造を促進します.
cALG8を標的にするASOとゲムシタビンと抗PD-1抗体は,PDXモデルにおける腫瘍負荷を著しく減少させた.

結論

cALG8/ CLK1/ SRSF7軸はATM発現を高め,ゲムシタビン耐性およびPDACにおける免疫抑制性腫瘍微環境を誘発する.
この研究は,PDACの化学療法抵抗を克服するために,DNA損傷修復メカニズムをターゲットにすることで,洞察を提供します.
cALG8を標的とするASOは,臓がんに対する有望な治療戦略です.

キーワード:

代替スプライシングゲムシタビン耐性管腺がん RNA結合タンパク質

関連する実験動画

自動的に一致したビデオです Contact us もしそれらが関連していない場合

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in <em>In Vitro</em> Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

See all related videos

関連する概念動画

RNA Splicing

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...

Alternative RNA Splicing

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

Share

X
Facebook
LinkedIn
YouTube

ABOUT JoVE

Overview
Leadership
Blog
JoVE Help Center

AUTHORS

Publishing Process
Editorial Board
Scope & Policies
Peer Review
FAQ
Submit

LIBRARIANS

Testimonials
Subscriptions
Access
Resources
Library Advisory Board
FAQ

RESEARCH

JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive

EDUCATION

JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Faculty Site

Terms & Conditions of Use
Privacy Policy
Policies